These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 18683146

  • 1. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC.
    Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 4. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
    Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze JF.
    Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
    [Abstract] [Full Text] [Related]

  • 5. Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
    Acosta-Tejeda M, Baptista-González H, Rosenfeld-Mann F, Trueba-Gómez R, García-Latorre E.
    Thromb Res; 2011 Oct; 128(4):e39-42. PubMed ID: 21708401
    [Abstract] [Full Text] [Related]

  • 6. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 7. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
    Sucker C, Hetzel GR, Farokhzad F, Dahhan F, Schmitz M, Kurschat C, Grabensee B, Maruhn-Debowski B, Zotz R, Scharf R.
    Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
    [Abstract] [Full Text] [Related]

  • 8. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 9. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
    Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR.
    Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
    [Abstract] [Full Text] [Related]

  • 10. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW, Liver and Thrombosis Study Group.
    Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
    [Abstract] [Full Text] [Related]

  • 11. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 13. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
    Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C.
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
    [Abstract] [Full Text] [Related]

  • 14. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction.
    Akatsu H, Yamagata H, Chen Y, Miki T, Kamino K, Takeda M, Campbell W, Kondo I, Kosaka K, Yamamoto T, Okada H.
    Br J Haematol; 2004 Nov; 127(4):440-7. PubMed ID: 15521922
    [Abstract] [Full Text] [Related]

  • 15. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Nov; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 16. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 17. [Study on plasma coagulation factor VII (FVII) levels and polymorphisms of FVII gene in patients with coronary heart disease].
    Kang W, Wang H, Xiong L, Wang X, Chu H, Qu B, Liu X, Yin J, Duan B, Yu J, Wang Z.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Sep; 23(9):457-9. PubMed ID: 12482354
    [Abstract] [Full Text] [Related]

  • 18. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
    Pruner I, Djordjevic V, Miljic P, Kovac M, Antonijevic N, Rakicevic L, Radojkovic D.
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
    [Abstract] [Full Text] [Related]

  • 19. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenço D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA, Zago MA.
    Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
    Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.
    Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.